Analyst Ratings For Dicerna Pharmaceuticals
Dicerna Pharmaceuticals (NASDAQ:DRNA) has observed the following analyst ratings within the last quarter:
Last 30 Days
1 Month Ago
2 Months Ago
Mid-Day Market Update: Gold Drops 2.5%; Sphere 3D Shares Spike Higher
Midway through trading Friday, the Dow traded up 0.46% to 35,225.33 while the NASDAQ fell 0.70% to 14,791.01. The S&P also rose, gaining 0.07% to 4,432.28.
RBC Capital Maintains Outperform on Dicerna Pharmaceuticals, Lowers Price Target to $30
RBC Capital analyst Luca Issi maintains Dicerna Pharmaceuticals (NASDAQ:DRNA) with a Outperform and lowers the price target from $35 to $30.
Mid-Morning Market Update: Markets Mostly Higher; US Economy Adds 943,000 Jobs
Following the market opening Friday, the Dow traded up 0.37% to 35,193.61 while the NASDAQ fell 0.26% to 14,857.09. The S&P also rose, gaining 0.16% to 4,436.02.
Goldman Sachs Maintains Buy on Dicerna Pharmaceuticals, Lowers Price Target to $36
Goldman Sachs maintains Dicerna Pharmaceuticals (NASDAQ:DRNA) with a Buy and lowers the price target from $48 to $36.
SVB Leerink Maintains Outperform on Dicerna Pharmaceuticals, Lowers Price Target to $47
SVB Leerink analyst Mani Foroohar maintains Dicerna Pharmaceuticals (NASDAQ:DRNA) with a Outperform and lowers the price target from $54 to $47.
Why Is Dicerna Stock Getting Slammed Today?
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) announced top-line results from PHYOX2 pivotal trial of nedosiran, RNAi therapeutic, for primary hyperoxaluria (PH). The trial…